Successful treatment with micafungin of invasive pulmonary aspergillosis in acute myeloid leukemia, with renal failure due to amphotericin B therapy

Annals of Hematology

Volumn 83, Issue 1, 2004, Pages 64-66

  Yokote, T ^a   Akioka, T ^a   Oka, S ^a   Fujisaka, T ^a   Yamano, T ^a   Hara, S ^a   Tsuji, M ^a   Hanafusa, T ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Acute myeloid leukemia; Amphotericin B; Invasive pulmonary aspergillosis; Micafungin; Renal failure

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B; ANTIFUNGAL AGENT; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; ITRACONAZOLE; MERCAPTOPURINE; MICAFUNGIN; MITOXANTRONE; VANCOMYCIN;

ADULT; ARTICLE; CASE REPORT; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; HUMAN; KIDNEY FAILURE; LUNG ASPERGILLOSIS; MALE; MYELOID LEUKEMIA; NEPHROTOXICITY; PRIORITY JOURNAL; RESPIRATORY FAILURE;

AMPHOTERICIN B; ASPERGILLOSIS; HUMANS; KIDNEY FAILURE; LEUKEMIA, MONOCYTIC, ACUTE; LIPOPROTEINS; LUNG DISEASES, FUNGAL; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; TREATMENT OUTCOME;

EID: 0347268948     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-003-0736-8     Document Type: Article

References (18)

1. Denning DW (1998) Invasive aspergillosis. Clin Infect Dis 26:781-803
2. Dannauoui E, Borel E, Persat F, Piens MA, Picot S (2000) Amphotericin B resistance of Aspergillus terreus in a murine medel of disseminated aspergillosis. J Med Microbiol 49:601-606
3. Meunier F (1994) Alternative modalities of administering amphotericin B: current issues. J Infect 28[Suppl 1]:51-6
4. Fanos V, Catalfi Ll (2000) Amphotericin B-induced nephrotoxicity: a review. J Chemother 12:463-470
5. Pretice HG, Caillot D, Dupont B (1999) Oral and intravenous itraconazole for systemic fungal infections in neutropenic haematological patients. Acta Haematol 101:56-62
6. Cornely OA, Ullmann AJ, Karthaus M (2003) Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood 101:3365-3372
7. Iwamoto T, Sakamoto N, Yamashita M (1993) FR90139, a novel antifungal antibiotic. In: Abstract 371 of the 33rd Intersci Conf Antimicrob Agents Chemother, New Orleans, 27-20 Oct
8. Ueda S, Tanaka M, Ezaki M (1998) Studies on a novel lipopeptide acylase(FR901379 acylase) from Streptomyces sp. for production of FR179642, a key intermediate of antifungal lipopeptide drug FK 463. In: Abstract F 145 of the 38th Intersci Conf Antimicrob Agents Chemother, San Diego, 24-27 Sept
9. Fromtling RA, Castner J (1998) FK-463. Drugs Future 23:1273-1278
10. Fromtling RA (2002) Micafungin sodium (FK-463). Drugs Today 38:245-257
11. Kohno S, Mitsutake K, Maesaki S, Yasuoka A, Miyazaki T, Kaku M, Koga H, Hara K (1993) An evaluation of serodiagnostic tests in patients with candidemia:beta-D-glucan, mannan, Candida antigen by Cand-Tec and D-arabinitol. Microbiol Immunol 37:207-212
12. Obayashi T, Yoshida M, Mori T, Goto H, Yasuoka A, Iwasaki H, Teshima H, Kohno S, Horiuchi A, Ito A (1995) Plasma(1 3)-beta-D-glucan determination in the diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 345:17-20
13. Warn PA, Morrissey G, Morrissey J, Denning DW (2003) Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terrus demonstrating in vivo resistance to Amphotericin B. J Antimicrob Chemother 51:913-919
14. Pettengell K, Mynhardt J, Kluyts T (2000) A multicentre study of the echinocandin antifungal FK 463 for the treatment of esophageal candidiasis in HIV positive patients. In: Abstract of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, Abstract 1104, p 371. American Society for Microbiology, Washington, DC, USA
15. Seibel NL, Schwartz C, Arrieta A (2000) Phase I study to determine the safety and Pharmacokinetics (PK) of FK463 (Echinocandin) in febrile neutropenic pediatric patients. In: Abstract of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, Abstract 18, p 1. American Society for Microbiology, Washington, DC, USA
16. Kohno S, Masaoka T, Yamaguchi (2001) A multicenter, open label clinical study of FK 463 in patients with deep mycosis in Japan. In: Abstract J-834 of the 41st Intersci Conf Antimicrob Agents Chemother, Chicago, 22-25 Sept
17. Kontoyiannis DP, Buell D, Frisbee-Hume S (2001) Initial experience with FK463 for the treatment of candidemia in cancer patients. In: Abstract J-1629 of the 41st Intersci Conf Antimicrob Agents Chemother, Chicago 22-25 Sept
18. Ullmann AJ, Van Burik JA, McSweeney P, Ratanatharathom V, Raymond J, de Morais VL, McGuirk J, Lau W, Facklam D, Koblinger S, Reusch M, Marr K, Patterson TF, Denning DW (2003) An open phase II study of the efficacy of micafungin (FK463) alone and in combination for the treatment of invasive aspergillosis (IA) in adults and children. 13th ECCMID meeting, Glasgow, Scotland, UK